Karyopharm Therapeutics Investor Presentation — September 2020

Document content

September 2020A Commercial -stage Pharmaceutical Company Pioneering

Novel Cancer Therapies2 ©2020 Karyopharm Therapeutics Inc. This presentation contains forward -looking statements within themeaning ofThePrivate Securities Litigation Reform Actof1995 .Such forward -looking statements include those regarding

Karyopharm’s expectations andplans relating toXPOVIO forthetreatment ofpatients withrelapsed orrefractory multiple myeloma orrelapsed orrefractory diffuse large B-celllymphoma ;

commercialization ofXPOVIO oranyofitsdrug candidates andthecommercial performance ofXPOVIO ;submissions to,andthereview andpotential approval ofselinexor by,regulatory

authorities, including theCompany’s regulatory strategy, theanticipated availability ofdata tosupport such submissions, timing ofsuch submissions andactions byregulatory authorities

andthepotential availability ofaccelerated approval pathways ;theexpected design oftheCompany’s clinical trials ;thetherapeutic potential ofandpotential clinical development plans for

Karyopharm's drug candidates, especially selinexor ;Karyopharm’s collaboration efforts with third-parties, including theNational Cancer Institute ;2020 financial expectations, including

forecasted non-GAAP R&D andSG&A expenses ;andexpectations ofthesufficiency ofKaryopharm’s existing cash andinvestments .Such statements aresubject tonumerous important

factors, risks anduncertainties, many ofwhich arebeyond Karyopharm's control, thatmay cause actual events orresults todiffer materially from Karyopharm's current expectations .For

example, there canbenoguarantee thatKaryopharm willsuccessfully commercialize XPOVIO ;thatregulators willagree thatselinexor qualifies forconditional approval intheE.U.asa